Introduction
Remarkable progress in our understanding of the pathobiology of myeloma (MM) has transformed the treatment paradigm and patient outcome. Preclinical studies have guided the discovery of more effective targeted therapies and informed clinical management. However, constitutive and ongoing genetic complexity and instability, coupled with the tumor promoting, immunosuppressive bone marrow (BM) microenvironment, remain an obstacle to cure. An estimated 32,270 new MM cases and 12,830 deaths in 2020 in the USA, 1 coupled with a worldwide 126% increase in MM cases from 1990 to 2016, 2 highlight the urgent need for novel therapies.
Definition of disease and precursor stages
Multiple myeloma is characterized by malignant plasma cells (PC) in the BM associated in most cases with monoclonal protein in serum and or urine; PC can also be detected in extramedullary sites and/or peripheral blood during progression of disease. 3 , 4 Examination for MM-defining events allows for the discrimination between MM and its precursor stages, namely monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). 5 Specifically, diagnosis of MM requires 10% or more PC in the BM plus one or more signs of end-organ damage including hypercalcemia, renal dysfunction, anemia, or bone disease (CRAB criteria). 4 Even without CRAB features, patients who manifest MM-defining events including clonal BM PC >60%, serum : ratio >100 fold, and/or more than one bone focal lesion on magnetic resonance imaging (MRI) or positron emission tomography (PET)/computed tomography (CT) scan are also treated, as their risk of progression to symptomatic disease is approximately 80% at 2 years. 5 , 6 Clinical manifestations of MM result from excessive production of monoclonal immunoglobulin protein by malignant PC in blood and/or urine, infiltration of BM by neoplastic clone, and aberrant cytokine secretion. 4 MGUS patients are monitored for progression off all therapy, as their risk of progression overall is 1% yearly. The standard of practice is also to follow SMM patients expectantly off treatment, 7 , 8 as the risk of progression is 10% per year in the first 5 years, dropping to 3% per year thereafter. Recently, the new “20-20-20” Mayo Clinic criteria have identified a high-risk (HR)-SMM subgroup (patients with two or more features including: BM PC infiltration >20%, monoclonal protein >20g/L and FLC ratio >20) with a median time to progression of 29 months. 9 The QuiRedex study showed that lenalidomide+dexamethasone treatment prolonged time to progression and overall survival (OS) in HR-SMM. 10 More recently lenalidomide alone has been shown to delay progressions of HR-SMM; 11 however, there was a high rate of treatment discontinuation and secondary cancers in the lenalidomide cohort. 11 Ongoing clinical trials are also evaluating alternative treatment strategies to delay progression of HR-SMM. 12 Most recently, next-generation sequencing (NGS) analysis of MGUSSMM- MM patients has proven to be a useful tool to decipher the timing and chronology of disease initiation events. 13 , 14 In the near future, the combination of genomic signatures and markers of disease burden will likely enable identification of those SMM patients who may benefit from early intervention, and definition of the optimal time to initiate treatment to avoid the development of clinical sequelae. Assessment of the value of early intervention must balance the benefit of delaying/preventing symptomatic MM against the risk of adverse events, and such early interventions should be of finite duration.
Prognostic factors and risk stratification
Clinical and laboratory factors including disease stage, cytogenetic abnormalities, and depth of response to therapy can impact survival of MM patients. 15 Cytogenetic analysis and fluorescence in situ hybridization (FISH)- based genetic profiling should be routinely performed to evaluate disease biological behavior and prognosis. 16 Among the poor prognostic markers, del(17p) and t(4;14) are the most informative; 17 , 18 concomitant secondary cytogenetic abnormalities may impact prognosis. 4 The International Staging System (ISS), based on albumin and β 2 -microglobulin levels, is most widely used, 19 and has been revised (R-ISS) to incorporate lactate dehydrogenase (LDH) and HR-FISH abnormalities. 20 Given the genomic complexity of MM, more sophisticated techniques including gene expression profiling, mutational status, and copy number abnormalities have been used, alone or in combination with FISH-based approaches, to more deeply characterize disease biology and prognosis. For example, newly diagnosed MM (NDMM) patients carrying HR del(17p) may be further stratified using subclonal analysis. 21 Targeted sequencing has been used as an alternative to whole exon sequencing to specifically analyze fractions of the genome and provide more accurate risk stratification. 22 Although not widely incorporated into clinical practice, these approaches will help to define future personalized treatment strategies in MM.
Assessment of response: minimal residual disease
The high rate of complete response (CR) observed with the introduction of novel agents has led to the need for metrics capable of detecting even deeper responses to be developed. Response criteria are based on assessment of monoclonal protein in serum and urine, as well as BM evaluation. However, these parameters alone are not sensitive enough to detect low levels of residual tumor cells in the BM. 23 More recently, both retrospective meta-analyses and prospective clinical trials have demonstrated the values of measuring minimal residual disease (MRD) within the BM using next-generation flow (NGF) or NGS, and at extramedullary sites using imaging such as PET/CT. 24 , 25 The International Myeloma Working Group (IMWG) updated response criteria now include MRD status defined by absence of BM PC by NSG or NGF with a minimum sensitivity of 1 in 10 5 nucleated cells in patients with CR, providing guidelines that can be uniformly interpreted and applied in the context of clinical trials. 26 MRD should be evaluated over the course of the disease, informing disease biology and treatment. 26 For example, the DFCI/IFM clinical trial comparing lenalidomide-bortezomib- dexamethasone followed by early versus late autologous stem cell transplant (ASCT) showed that MRD negativity at the level of 10 -6 was associated with prolonged progression-free survival (PFS) and OS. 27 , 28 Moreover, those patients with MRD-BM who were also imaging (PET/CT scan) MRD negativity had the best outcome. 27 , 28 Whether MRD-negativity should represent the goal of therapy for all patients with NDMM or relapsed/refractory (RRMM), or whether treatment decisions should be predicated on MRD status, is still the focus of ongoing clinical trials.
Biologically-based treatments
High-dose chemotherapy plus ASCT remains the standard of care for NDMM patients of physiologic age 70 years or younger who have adequate cardiac, pulmonary, hepatic and renal function. 4 Patients who are ineligible for transplant receive induction regimens dependent upon their frailty status. 4 In both groups, the integration of scientifically- informed combinations of novel agents including immunomodulatory drugs (IMiD), proteasome inhibitor (PI), dexamethasone, and more recently monoclonal antibodies (mAbs), has transformed the treatment paradigm and patient outcome. However, genomic and clonal evolution in the tumor-promoting BM milieu underlies relapse of disease in most patients, and novel therapies are urgently needed.
Direct targeting of multiple myeloma cell dependencies
- Multiple myeloma “lineage” dependencies
Tumor cells may crucially rely on survival mechanisms that are imprinted during lineage development, namely lineage-dependency. 29 For example, the clinical success of first-in-class PI bortezomib in MM has validated the heightened dependency of MM cells on the protein quality control pathway as a therapeutic target. 30-32 The ubiquitin- proteasome system (UPS) is the primary mechanism for maintaining protein homeostasis. 33 In normal PC, high protein turnover due to immunoglobulin production requires intact proteasome function, and this dependency is even higher in MM PC with aberrant protein turnover which further increases proteasome load. PI can overwhelm the imbalance between proteasome degradative capacity and proteasome load, 34-36 leading to endoplasmic reticulum stress due to accumulation of misfolded and unfolded proteins, activation of the unfolded protein response, and cell death. Since proteins involved in cell proliferation and apoptosis, cell-cycle, DNA repair, and metabolism are substrates of the proteasome, PI inhibitor bortezomib has broad effects. 37 , 38 It triggers both intrinsic and extrinsic MM cell apoptosis and MM cell cycle arrest, and modifies bone turnover and osteoclast activity in the BM. 38 Bortezomib inhibits the NFκB pathway by blocking degradation of its inhibitor, IκB. 33 , 38 Importantly, NFκB is a major oncogenic pathway in MM, which mediates MM survival and DNA repair, promotes interactions of MM cells-BM accessory cells via the transcription of adhesion molecules, as well as modulating transcription of cytokines (such as IL-6, VEGF, IGF-1), which in turn mediate MM growth and drug resistance, and confer immunosuppression in the BM. 33 , 38
Over the disease course, MM cells acquire resistance to bortezomib via genetic and non-genetic mechanisms. 33 Extensive preclinical research has delineated mechanisms
of PI resistance and informed strategies to overcome resistance. Second-generation PI have been generated to overcome bortezomib resistance. The irreversible covalent epoxyketone PI carfilzomib, either alone or in combination with lenalidomide, has been approved to treat RRMM. 39 Ixazomib, the first oral boronic acid-based PI, has been approved, alone and in combination with lenalidomide, to treat RRMM; 40 this all-oral regimen showed low toxicity profile and improved patient quality of life. The pan-PI marizomib, which penetrates the central nervous system (CNS), also demonstrates anti-MM activity in the setting of bortezomib resistance. 41 Given the multitude of available PI, the side effect profiles and identification of biomarkers of PI resistance/sensitivity will determine their optimal and rational use.
Targeting upstream components of the ubiquitin proteasome system (UPS) has recently emerged as a promising strategy to overcome PI resistance. Therapeutic targeting of deubiquitylating enzymes (DUB) and the 19S proteasome- associated ubiquitin receptor Rpn13 overcame PI resistance in preclinical studies. 42-45 However, the first-inhuman trial of USP14/UCHL5 DUB inhibitor for RRMM has been stopped due to dose-limiting toxicity. Targeted therapies against Rpn13 have been developed for evaluation in setting of PI resistance. 46 An alternative approach to overcome PI resistance is the concomitant block of the aggresome/autophagy pathway using an inhibitor of histone deacetylase 6 (HDAC6), which is recruited to maintain proteostasis balance as an adaptive response mechanism. 38
Lineage vulnerabilities in MM also include aberrant transcription factor (TF) regulatory networks controlling lineage factor IRF4. 47 Although direct targeting of TF represents an attractive strategy, there are no available inhibitors for clinical application. However, we found that aberrant regulatory KDM3A-IRF4-KLF2 loop may be efficiently targeted by KDM3A inhibitor, which restores IRF4 and KLF2 promoter methylation and suppresses their transcription, thereby resulting in decreased MM cell homing to the BM and direct anti-MM toxicity. 48 Moreover, repression of IRF4 transcription is observed after lenalidomide treatment, which triggers cereblon (CRBN)-mediated degradation of IRF4 transcriptional activator IKZF3. 49 , 50 From these findings, a new platform technology has been developed to trigger selective protein degradation. Specifically, degronimids, also known as proteolysis-targeting chimeras (PROTAC), are designed by conjugating the small-molecule binder of the target protein to an E3 ubiquitin ligase binding scaffold, such as the analogs of thalidomide which bind CRBN. 51 This approach will allow for the therapeutic degradation of protein substrates that are otherwise challenging to target.
- Multiple myeloma “clonal” dependencies
Large inter-patient and intra-patient genetic heterogeneity limits the identification of universal drivers of MM. However, several oncogenic dependencies are primary events related to mutations in driver genes and primary translocations. 52 Translocations or gains of MYC locus (along with dysregulation of upstream signaling pathways, such as IRF4) support an oncogenic role of MYC in MM, especially in the context of MGUS-MM transition. 53 Alteration of the transcriptional program of MYC, and of its functional collaborators such as E2F1, promotes oncogenic signaling and PC survival. 54 , 55 Frequent gene mutations in MM include RAS , either KRAS or NRAS , with subsequent activation of the MAPK pathway, BRAF , DIS3 , and FAM46C . 56 Their role as prognostic factors has not been completely defined, as only TP53 mutation (6-8% of patients at diagnosis) clearly confers worse patient outcome. 57 Mutation-targeted treatments in MM are often compromised by intra-clonal heterogeneity. Specifically, deep sequencing has identified a complex subclonal structure in MM with different patterns of clonal evolution impacted by BM, immune response, and therapy. 58 In this complex scenario, MM cells may share common mutations, but they may also express additional subclones which compromise mutation-targeting therapies. 58 , 59 The MyDRUG trial is enrolling patients with relapsed MM based upon genomic sequencing; patients receive a specific treatment targeting their unique tumor mutations, along with standard-of-care treatment. 60 This trial will reveal whether the abnormal clone can be targeted, and provide the rationale for further derived clinical trials of targeted therapies.
Genomic complexity in MM is due to genomic instability and ongoing DNA damage. 61 MM cells display hyperactivation of DNA repair mechanisms which confer a survival advantage and drug resistance with increasing numbers of new mutations over time. 62 These aberrant processes may reveal new vulnerabilities. For example, in MM patients, in whom ongoing DNA damage occurs concurrently with low Hippo co-transcription factor (YAP1) levels, MM cell apoptosis is prevented. Conversely, inhibition of STK4 rescues YAP1 and triggers DNA-damageinduced apoptosis, providing the framework for clinical evaluation of STK4 inhibition. 63 A second example is the induction of “BRCAness” status in MM cells by bortezomib, thereby increasing their sensitivity to PARP inhibitors. 37 Finally, MYC amplification in MM can induce DNA response pathway and reactive oxygen species; the former can be blocked by ATR inhibitors and the latter can be increased by bortezomib, together triggering MM cell apoptosis in a synthetic lethal mechanism. 61
- Multiple myeloma epigenetic modifications
Epigenetic alterations affect regulation of gene activity and expression, without altering gene sequence. Such alterations are associated with MM onset and progression, and modulate several important biological processes. 64 Among epigenetic changes, DNA methylation, histone modification, and non-coding RNA (ncRNA) deregulation are the best characterized. 64 Global hypomethylation of the genome characterizes the transition from MGUS to MM, whereas pervasive genome re-methylation occurs in the transition from MM to more aggressive leukemic stage (PCL). 64 Universal overexpression of histone methyltransferase MMSET is detected in patients carrying t(4;14) translocation and promotes MM cell survival by activating oncogenic MAPK pathway, increasing MYC and IRF4 transcription, and inducing chemo-resistance through enhancing DNA repair mechanisms. 65 , 66 Therefore, development of MMSET inhibitor represents a promising therapeutic strategy for this subset of MM. We have demonstrated the oncogenic role and prognostic relevance of type II arginine methyltransferase PRMT5 in MM, whose inhibition results in MM cell killing via NFκB inhibition, thus providing the rationale for clinical trials targeting PRMT5 in MM. 67
Histone deacetylases (HDAC) are generally hyperactive in MM, and HDAC inhibitors are the most investigated epigenetic drugs. 65 Preclinical studies have led to clinical trials and the approval of non-selective HDAC inhibitor panobinostat in combination with bortezomib in RRMM. 68 However, increased toxicity observed with panobinostat prompted the development and translation of selective HDAC6 inhibitors (ricolinostat and ACY 241), which showed promising results and lower toxicity in combination with bortezomib and dexamethasone. 69 , 70
Over the last decade, extensive studies have also highlighted the contribution of the ncRNA compartment in MM pathogenesis and progression. Specifically, microRNAs (miRNAs) are key regulators of gene expression at the post-transcriptional level, as they can induce either translational repression or degradation of target mRNAs upon total or partial complementary binding with 3′ untranslated region (3′ UTR). 71 Given the multitude of targets for a single miRNA, these molecules harbor the potential to concomitantly regulate multiple biological processes. Preclinical data have defined their oncogenic (miR-221/222,-21,-17-92 cluster) or tumor suppressive (miR-29b,-34a,-125b,-15,-16) roles in MM associated with repression or overexpression, respectively, of genes involved in essential pro-survival pathways. 72-77 The role of miRNAs has been similarly investigated in the context of drug resistance, BM-PC interaction, and bone disease. 78-81 Although miRNA-based therapeutics have not yet translated into US Food and Drug Administration (FDA)- approved drugs, several candidates are being tested in other diseases and will soon be evaluated in MM, 82 using miRNA replacement or inhibition strategies. As they are endogenous antisense of mRNAs, their replacement is likely to induce a “natural” effect on the targets, with less off-target effects compared to siRNAs; moreover, the recent availability of in vivo delivery systems now allows for clinical trials. 83 Likewise, miRNA inhibition strategies take advantage of new antisense oligonucleotide technologies, and ongoing early trials in several cancers will likely pave the way for their investigation in MM. 83 Finally, long ncRNAs (lncRNA) represent major regulators of gene expression and chromatin dynamics by interacting with DNA and proteins. 84 LncRNA genes outnumber protein- coding genes, with a partner of expression often restricted to specific cell types or conditions. 84 With few exceptions, however, their functional role is still largely obscure in MM. 85 We recently described the lncRNA landscape in MM, and their role as independent predictors of clinical outcome; 86 ongoing and future studies will define their role in disease pathogenesis and as potential therapeutic targets.
Targeting the tumor-bone marrow microenvironment interface
Disrupting the interactions of MM cells with the BM represents an ideal therapeutic strategy in MM, as shown by agents such as IMiD which remain active against MM even in the BM milieu . Cellular and non-cellular components of the BM niche support MM cell proliferation, migration, survival and drug resistance, while also conferring immunosuppression, and therefore represent targets for novel therapeutics. 4 , 87 , 88
- Immunomodulatory drugs
Extensive preclinical and clinical studies have led to the FDA approval of the IMiD thalidomide and its more potent derivatives lenalidomide and pomalidomide for treatment of both NDMM and RRMM. 89-92 IMiD induce direct cytotoxic effects on MM cells including growth arrest and caspase-8-mediated apoptosis, associated with CRBN-dependent degradation of IKZF1/3 followed by IRF4 downregulation. 49 , 50 , 93 In the BM microenvironment they abrogate MM cell adhesion to the BM, modulate cytokine and growth factor secretion, inhibit angiogenesis, and most importantly, upregulate T, NK, and NKT cells, while downregulating regulatory T cells. 3 , 93 Mechanistically, binding to CRBN has also been implicated in mediating the immune-related effects of IMiD, as IKZF1/3 degradation in T cells increases their secretion of cytokines including IL-2. 94 This mechanism is also associated with increased natural killer (NK) and NK-T-cell cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) (i.e., anti-CD38, daratumumab and -CD20, rituximab) observed after IMiD treatment. 95 , 96 Furthermore, IMiD can also enhance NK and T-cell cytotoxicity by triggering granzyme-B via either CRBN- or ZAP-70-dependent mechanisms. 95 Preclinical and clinical studies have already confirmed the strong synergism of IMiD with PI and with mAb. 97-102 Recently, iberdomide, a higher affinity CRBN E3-ligase modulator (CELMoD), showed significant preclinical activity against IMiD-resistant MM cells, 103 and ongoing clinical trials are examining its efficacy in RRMM resistant to lenalidomide and pomalidomide. Promising results have also been recently reported with the more potent CELMoD CC-92480, currently under investigation to treat IMiD-resistant RRMM. 104
- Immune-based therapies
Loss of immune surveillance supports MM growth and resistance, and is associated with alterations in accessory and immune cells in the BM. 105 Moreover, there is increasing evidence that evolving immune dysfunction is an important determinant of progression from MGUS/SMM to symptomatic MM. 105 For example, functional interaction of plasmacytoid dendritic cells (DC) with MM cells promotes their survival and drug resistance, 106 providing the framework for targeting this interaction in novel therapies. 107-109 Similarly, myeloid derived suppressor cells, regulatory T cells, Th17 cells, tumor-associated macrophages, mesenchymal stromal cells, and osteoclasts significantly contribute to tumor immune escape and immunocompromised clinical status. 110 Immune escape is also mediated, at least in part, by increased expression of immune checkpoints, i.e., PD-1/PD-L1, in T cells and MM cells, associated with disease progression from MGUS and SMM to MM. 111 Although preclinical data have suggested the therapeutic utility of PD-1/PD-L1 blockade, early clinical trials have been discouraging. 111 No singleagent activity of pembrolizumab has been shown, and importantly, two randomized clinical trials evaluating pembrolizumab in combination with IMiD to treat RRMM were closed due to excessive mortality. 111 Ongoing studies are characterizing the role of the other immune checkpoint or agonist proteins (i.e., LAG 3 or TIGIT and OX40, respectively) as potential therapeutic targets, alone and in combination with MM targeted and immune therapies. 112 Multiple mAb targeting MM surface antigens can trigger ADCC, antibody-dependent cellular phagocytosis, complement activation, and direct effect on MM cells. 113 Elotuzumab and daratumumab target SLAMF7 and CD38, respectively. 113 Elotuzumab also directly activates NK cells and is FDA approved in combination with lenalidomide or pomalidomide in RRMM. 99 , 100 Daratumumab has shown remarkable extent and frequency of response, leading to its FDA approval as a single agent or in combination with IMiD and PI in both RRMM and NDMM. 97 , 98 , 114 , 115 The recent GRIFFIN trial compared standard lenalidomide-bortezomib-dexamethasone with or without daratumumab in transplant eligible patients, and showed deeper responses and MRD negativity rate in the daratumumab-treated patient cohort. 116 Moreover, recent approval of subcutaneous formulation of daratumumab will dramatically reduce patient treatment times. 117 More recently, a new CD38- directed mAb, isatuximab, has been approved in combination with pomalidomide-dexamethasone to treat RRMM; 101 whether it is effective even in daratumumab refractory MM remains to be determined.
Monoclonal antibody technologies have also provided the framework for the development of Ab-drug conjugates (ADC) and bispecific T-cell engagers (BiTE). In the former, the conjugation with cytotoxic chemicals (such as auristatin) via synthetic linkers provides for direct tumor killing, and the mAb provides for selective tumor cell targeting, as well as immune-mediated cytotoxicity. 118-122 Bcell maturation antigen (BCMA)-directed ADC are currently under investigation in both preclinical and clinical settings, and represent a promising approach due to the highly specific expression on BCMA on MM cells and late memory B cells, as well as the role of the BCMA/APRIL pathway in supporting MM cell survival in the BM. 113 , 118 , 123 The bi-specificity of the BiTE (mainly for CD3 on T cells and several MM-associated antigens, such as BCMA and GPRC5D) allows for engagement of T cells with tumor cells, resulting in formation of cytolytic synapses and tumor lysis. 124-126 Although results from early trials look promising, longer follow-up in larger studies are needed to assess the clinical benefit and potential toxicity. Importantly, BCMA ADC and BiTE have the advantage for “off the shelf” availability and universal use.
Cellular therapies represent an additional strategy to boost MM-specific immunity using either adoptive T-cell (ACT) or engineered T-cell approaches. 3 Clinical experience with ACT using marrow-infiltrating lymphocytes (MIL) in MM has shown promise in achieving memory immune responses and stable disease. 127 Importantly, advances in engineering technologies have allowed for both T-cell receptor (TCR) and chimeric antigen receptor (CAR) T-cell approaches. 128 CAR are chimeric proteins that bring together the signaling moieties of TCR complexes and the variable domains of Ab which recognize a tumor-associated antigen. 128 , 129 Co-stimulatory molecules have been included in the second-generation CAR-T cells to enhance T-cell activation by mimicking a physiological T-cell response. 128 , 129 After genetic modification, a patient’s T cells expressing the chimeric protein can be expanded ex vivo , and then activate a specific T-cell response once reinfused to the patient. 128 , 129 This allows CAR-T cells, in contrast to TCR-T cells, to recognize unprocessed tumor antigen in an MHC-independent manner. 128 , 129 A major determinant of successful CAR-T therapy is the identification of a target uniquely and highly expressed by MM cells, thus limiting the occurrence of “off-target” effects. Among a variety of antigen targets, BCMA is the most frequently used due to its selectivity for normal plasma and MM cells. Several CAR-T products have been clinically tested in heavily pre-treated (PI-IMiD-CD38 mAb) RRMM, and have demonstrated remarkable deep (MRD - ) responses. 129-132 Clinical experience has also helped to improve management of the most commonly observed toxicities of CAR-T cells, including cytokine release syndrome and neurotoxicity. 128 , 129 To date, however, most patients have relapsed, and ongoing research is assessing mechanisms of resistance to CAR-T, utilizing combination immune approaches with CAR-T, and using CAR-T earlier in the disease course in order to achieve more durable responses.
Lastly, vaccination strategies have been developed to improve antigen-specific memory anti-MM immunity. Specifically, multi-peptide-based vaccines induce effective and durable memory peptide-specific CTL in SMM patients, providing the rationale for their clinical evaluation to delay progression from SMM to active disease. 133 , 134 More recently, a novel engineered heteroclitic BCMA peptide has been used to induce a BCMA-specific memory anti-MM immunity, suggesting its potential use in vaccination and/or ACT strategies to generate longlasting immunity against MM. 135 As alternative vaccination strategy employs MM cell/DC fusion vaccines to generate anti-MM immunity in the post-ASCT setting, this vaccine induces anti-MM immunity and enhances depth of response. 136 The most significant obstacle to successful vaccination therapy in MM is the disease- and treatment-related immune dysfunction, which may limit the immune responses in vivo . As such, a randomized trial comparing lenalidomide versus lenalidomide plus MM cell/DC fusion vaccine post-transplant is ongoing ( clinicaltrials. gov identifier: NCT02728102 ) to determine whether combination of vaccination with IMiD may improve its efficacy. Overall, future treatment approaches will likely rely on the optimal combination of targeted and immunebased strategies to obtain a durable anti-MM response and restore the host immune-surveillance.
Future directions
Despite tremendous advances, the clinical management of MM patients remains challenging, since acquisition of resistance underlies relapse of disease in most patients. Correlative science studies on patient samples are delineating mechanisms of resistance to both targeted and immune agents in order to inform clinical strategies to overcome resistance and improve patient outcome. Development of second-generation more potent drugs of the same class has overcome both PI and IMiD resistance, as have combination therapies with agents targeting pathways mediating resistance. Identification of biomarkers of patient MM resistance/sensitivity may further inform sequential and combination therapies in the future. Importantly, agents targeting novel MM vulnerabilities are urgently needed. For example, selinexor, a selective inhibitor of nuclear export of tumor suppressor proteins, growth factors, and mRNAs of oncogenic proteins, has recently been approved in triple-class (PI-IMiD-anti-CD38 mAb) refractory MM. 137
A similar scenario of resistance is now beginning to appear for immune-based approaches, with several possible explanations. Loss of targeted antigens (such as BCMA, CD38) is a common event, either due to loss with tumor evolution or to suppression in the face of immune pressure. Multi-antigen targeting may potentially overcome this obstacle, and several trials are evaluating this strategy. 129 Similarly, circulating antigen in a soluble form may potentially interfere with immune-targeted approaches. For example, high levels of soluble BCMA have been detected in MM patients, and anti-BCMA CAR-T therapy is being combined with γ-secretase inhibitor to block BCMA cleavage from the MM cell surface ( clinicaltrials.gov identifier: NCT03502577 ). Additional resistance may be intrinsic to the technology or modality, and ongoing efforts to increase CAR-T cell expansion and persistence in vivo include enriching for early memory Tcell phenotype, optimizing CAR design to avoid antigenindependent tonic signaling, and/or intensifying lymphodepletion to promote CAR-T cell persistence. 129
Lastly, T-cell exhaustion and the immunosuppressive BM may contribute to both targeted- and immune-therapy resistance. 128 Restoration of host anti-MM immunity represents an important unmet need in MM. Several models, such as SCID-hu and SCID-synth-hu, have been developed to recapitulate the in vivo growth on patient MM cells in the context of BM. 138 , 139 However, understanding the role of the immune system in disease pathobiology requires the use of immunocompetent models (such as the 5T and Vk*MYC). 53 , 140 This is critical for evaluating not only immune therapies, but also targeted MM agents, such as bortezomib, which induce immunogenic cell death in vivo .
A recent area of investigation in MM is assessing the role of gut microbiome in shaping the immune system response, including anti-tumor immunity. For example, a commensal bacterium Prevotella heparinolytica promotes progression of MM by favoring differentiation of Th17 cells in the gut, which migrate to the BM of Vk*MYC mice and activate eosinophils; targeting IL-17-eosinophil immune axis may, therefore, represent a potential treatment for HR-SMM. 141 Abundance of Eubacterium limosum bacteria in the intestinal flora has been associated with relapse after allogeneic stem cell transplantation. 142 Similarly, high presence of Eubacterium hallii i n the intestinal microbiota correlates with achievement of MRD negativity. 143 Although still in an early stage, studies of the MM microbiome may identify future biomarkers or therapeutic agents to improve MM patient outcome.
Finally, identification of specific biomarkers predictive of therapy response within a patient’s heterogeneous MM has been a major focus of research. The first example of biomarker-driven anti-MM treatment in MM is the Bcl-2 inhibitor venetoclax, whose safety and efficacy are predicated upon occurrence of t(11;14) or presence of high levels of BCL2. 144 Several trials in RRMM are showing efficacy of venetoclax, as monotherapy and in combination, restricted to this patient subset. 145 , 146 Integration of current and future technologies may further guide disease management and allow for precision medicine. For example, encouraging results have recently been reported in a trial using a multi-omics approach integrating DNA and RNA sequencing to inform drug treatment for RRMM. 147 The ongoing MyDRUG trial profiles relapsed MM, and is then examining whether targeting genomic abnormalities in combination with standard relapse MM therapy can delete the abnormal MM clone. 60 This and other trials will inform the utility of precision medicine in MM, especially in the presence of concomitant genetic abnormalities.
Given the multiple available treatment options, welldesigned randomized clinical trials are necessary to assess the superior efficacy of specific regimens with head-tohead comparison. For example, interim analysis of the phase III ENDURANCE trial did not show superior PFS of carfilzomib versus bortezomib in combination with lenalidomide-dexamethasone for NDMM. Importantly, regulatory randomized trial results require real-world validation, since patient age, frailty status, and comorbidity frequently do not reflect trial patients. High-dose melphalan with ASCT remains a standard of care, and its role in the era of novel therapies is under evaluation in the IFM/DFCI 2009 DETERMINATION and FORTE clinical trials. However, the recent use of quadruplet therapies including daratumumab in the CASSIOPEIA and GRIFFIN trials shows that the addition of mAb can achieve increased extent and depth of response to induction therapy, 116 , 148 and whether high-dose melphalan and ASCT improves outcome of quadruplet therapy remains to be determined. Nonetheless, research continues to improve alkylating agents as well. For example, melflufen is a prodrug which is digested to melphalan by high levels of aminopeptidase in MM cells, thereby improving its therapeutic index. 149 , 150 Ultimately, the future use of novel targeted and immune therapies, as well as the role of conventional therapies, will be defined by vulnerabilities within individual patients and/or patient subgroups.
Conclusions
Over the past decades, a deeper understanding of the complex MM pathobiology has informed drug development and clinical practice, resulting in significant improvements in patient outcome. Combination approaches targeting MM cells, disrupting MM cell/BM interactions, and enhancing anti-MM immune responses, have remarkably improved response extent and frequency. Remaining obstacles to cure include constitutive and evolving genomic heterogeneity in MM cells, as well as the immunosuppressive BM milieu. In the future, integration of advanced sequencing technologies profiling both the MM cell and BM accessory/immune cells will identify novel targets and inform more potent, selective, and well tolerated targeted and immune therapies. Long-term disease- free survival and potential cure in MM will require both achieving MRD negativity and restoring host anti- MM immunity. Such patients can then be free of disease while off all therapies.
Supplementary Material
References
1. National Cancer Institute . Cancer stat facts: myeloma . Available from: https://seer.cancer.gov/statfacts/html/mulmy.html . Accessed 20 July 2020 .
2. Cowan AJ Allen C Barac A . Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016 . JAMA Oncol . 2018 ; 4 ( 9 ): 1221 - 1227 . 29800065 10.1001/jamaoncol.2018.2128 PMC6143021
3. Anderson KC . Progress and paradigms in multiple myeloma . Clin Cancer Res . 2016 ; 22 ( 22 ): 5419 - 5427 . 28151709 10.1158/1078-0432.CCR-16-0625 PMC5300651
4. Kumar SK Rajkumar V Kyle RA . Multiple myeloma . Nat Rev Dis Primers . 2017 ; 3 : 17046 . 28726797 10.1038/nrdp.2017.46
5. Rajkumar SV Dimopoulos MA Palumbo A . International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma . Lancet Oncol . 2014 ; 15 ( 12 ): e538 - 548 . 25439696 10.1016/S1470-2045(14)70442-5
6. Mateos MV Hernandez MT Giraldo P . Lenalidomide plus dexamethasone for highrisk smoldering multiple myeloma . N Engl J Med . 2013 ; 369 ( 5 ): 438 - 447 . 23902483 10.1056/NEJMoa1300439
7. Kyle RA Greipp PR . Smoldering multiple myeloma . N Engl J Med . 1980 ; 302 ( 24 ): 1347 - 1349 . 7374679 10.1056/NEJM198006123022405
8. Kapoor P Rajkumar SV . Smoldering multiple myeloma: to treat or not to treat . Cancer J . 2019 ; 25 ( 1 ): 65 - 71 . 30694862 10.1097/PPO.0000000000000350
9. Lakshman A Rajkumar SV Buadi FK . Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria . Blood Cancer J. 2018 ; 8 ( 6 ): 59 . 29895887 10.1038/s41408-018-0077-4 PMC5997745
10. Mateos MV Hernandez MT Giraldo P . Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial . Lancet Oncol . 2016 ; 17 ( 8 ): 1127 - 1136 . 27402145 10.1016/S1470-2045(16)30124-3
11. Lonial S Jacobus S Fonseca R . Randomized trial of lenalidomide versus observation in smoldering multiple myeloma . J Clin Oncol . 2020 ; 38 ( 11 ): 1126 - 1137 . 31652094 10.1200/JCO.19.01740 PMC7145586
12. D'Agostino M Bertamini L Oliva S Boccadoro M Gay F. Pursuing a curative approach in multiple myeloma: a review of new therapeutic strategies . Cancers (Basel) . 2019 ; 11 ( 12 ). 10.3390/cancers11122015 PMC6966449 31847174
13. Rustad EH Yellapantula V Leongamornlert D . Timing the initiation of multiple myeloma . Nat Commun . 2020 ; 11 ( 1 ): 1917 . 32317634 10.1038/s41467-020-15740-9 PMC7174344
14. Aktas Samur A Minvielle S Shammas M . Deciphering the chronology of copy number alterations in multiple myeloma . Blood Cancer J . 2019 ; 9 ( 4 ): 39 . 30914633 10.1038/s41408-019-0199-3 PMC6435669
15. Rajkumar SV . Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management . Am J Hematol . 2016 ; 91 ( 7 ): 719 - 734 . 27291302 10.1002/ajh.24402 PMC5291298
16. Sonneveld P Avet-Loiseau H Lonial S . Treatment of multiple myeloma with highrisk cytogenetics: a consensus of the International Myeloma Working Group . Blood . 2016 ; 127 ( 24 ): 2955 - 2962 . 27002115 10.1182/blood-2016-01-631200 PMC4920674
17. Avet-Loiseau H Hulin C Campion L . Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome experience . J Clin Oncol . 2013 ; 31 ( 22 ): 2806 - 2809 . 23796999 10.1200/JCO.2012.46.2598 PMC3718879
18. Kumar S Fonseca R Ketterling RP . Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics . Blood . 2012 ; 119 ( 9 ): 2100 - 2105 . 22234687 10.1182/blood-2011-11-390658 PMC3311247
19. Greipp PR San Miguel J Durie BG . International staging system for multiple myeloma . J Clin Oncol . 2005 ; 23 ( 15 ): 3412 - 3420 . 15809451 10.1200/JCO.2005.04.242
20. Palumbo A Avet-Loiseau H Oliva S . Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group . J Clin Oncol . 2015 ; 33 ( 26 ): 2863 - 2869 . 26240224 10.1200/JCO.2015.61.2267 PMC4846284
21. Thakurta A Ortiz M Blecua P . High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma . Blood . 2019 ; 133 ( 11 ): 1217 - 1221 . 30692124 10.1182/blood-2018-10-880831 PMC6428662
22. Bolli N Biancon G Moarii M . Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups . Leukemia . 2018 ; 32 ( 12 ): 2604 - 2616 . 29789651 10.1038/s41375-018-0037-9 PMC6092251
23. Paiva B van Dongen JJ Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma . Blood . 2015 ; 125 ( 20 ): 3059 - 3068 . 25838346 10.1182/blood-2014-11-568907 PMC4513329
24. Perrot A Lauwers-Cances V Corre J . Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma . Blood . 2018 ; 132 ( 23 ): 2456 - 2464 . 30249784 10.1182/blood-2018-06-858613 PMC6284215
25. Munshi NC Avet-Loiseau H Rawstron AC . Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis . JAMA Oncol . 2017 ; 3 ( 1 ): 28 - 35 . 27632282 10.1001/jamaoncol.2016.3160 PMC5943640
26. Kumar S Paiva B Anderson KC . International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma . Lancet Oncol . 2016 ; 17 ( 8 ): e328 - e346 . 27511158 10.1016/S1470-2045(16)30206-6
27. Moreau P Attal M Caillot D . Prospective evaluation of magnetic resonance imaging and [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study . J Clin Oncol . 2017 ; 35 ( 25 ): 2911 - 2918 . 28686535 10.1200/JCO.2017.72.2975 PMC5578392
28. Attal M Lauwers-Cances V Hulin C . Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma . N Engl J Med . 2017 ; 376 ( 14 ): 1311 - 1320 . 28379796 10.1056/NEJMoa1611750 PMC6201242
29. Garraway LA Sellers WR . Lineage dependency and lineage-survival oncogenes in human cancer . Nat Rev Cancer . 2006 ; 6 ( 8 ): 593 - 602 . 16862190 10.1038/nrc1947
30. Richardson PG Sonneveld P Schuster M . Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-toevent results of the APEX trial . Blood . 2007 ; 110 ( 10 ): 3557 - 3560 . 17690257 10.1182/blood-2006-08-036947
31. Richardson PG Sonneveld P Schuster MW . Bortezomib or high-dose dexamethasone for relapsed multiple myeloma . N Engl J Med . 2005 ; 352 ( 24 ): 2487 - 2498 . 15958804 10.1056/NEJMoa043445
32. Richardson PG Barlogie B Berenson J . A phase 2 study of bortezomib in relapsed, refractory myeloma . N Engl J Med . 2003 ; 348 ( 26 ): 2609 - 2617 . 12826635 10.1056/NEJMoa030288
33. Gandolfi S Laubach JP Hideshima T Chauhan D Anderson KC Richardson PG . The proteasome and proteasome inhibitors in multiple myeloma . Cancer Metastasis Rev . 2017 ; 36 ( 4 ): 561 - 584 . 29196868 10.1007/s10555-017-9707-8
34. Cenci S Mezghrani A Cascio P . Progressively impaired proteasomal capacity during terminal plasma cell differentiation . EMBO J . 2006 ; 25 ( 5 ): 1104 - 1113 . 16498407 10.1038/sj.emboj.7601009 PMC1409720
35. Bianchi G Oliva L Cascio P . The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition . Blood . 2009 ; 113 ( 13 ): 3040 - 3049 . 19164601 10.1182/blood-2008-08-172734
36. Obeng EA Carlson LM Gutman DM Harrington WJ Jr Lee KP Boise LH . Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells . Blood . 2006 ; 107 ( 12 ): 4907 - 4916 . 16507771 10.1182/blood-2005-08-3531 PMC1895817
37. Neri P Ren L Gratton K . Bortezomibinduced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors . Blood . 2011 ; 118 ( 24 ): 6368 - 6379 . 21917757 10.1182/blood-2011-06-363911 PMC4348156
38. Hideshima T Anderson KC . Biologic impact of proteasome inhibition in multiple myeloma cells-from the aspects of preclinical studies . Semin Hematol . 2012 ; 49 ( 3 ): 223 - 227 . 22726545 10.1053/j.seminhematol.2012.04.006 PMC3383768
39. Stewart AK Rajkumar SV Dimopoulos MA . Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma . N Engl J Med . 2015 ; 372 ( 2 ): 142 - 152 . 25482145 10.1056/NEJMoa1411321
40. Moreau P Masszi T Grzasko N . Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma . N Engl J Med . 2016 ; 374 ( 17 ): 1621 - 1634 . 27119237 10.1056/NEJMoa1516282
41. Richardson PG Zimmerman TM Hofmeister CC . Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1 . Blood . 2016 ; 127 ( 22 ): 2693 - 2700 . 27009059 10.1182/blood-2015-12-686378 PMC5413296
42. Song Y Li S Ray A . Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance . Oncogene . 2017 ; 36 ( 40 ): 5631 - 5638 . 28581522 10.1038/onc.2017.172 PMC5705032
43. Chauhan D Tian Z Nicholson B . A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance . Cancer Cell . 2012 ; 22 ( 3 ): 345 - 358 . 22975377 10.1016/j.ccr.2012.08.007 PMC3478134
44. Tian Z D'Arcy P Wang X . A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance . Blood . 2014 ; 123 ( 5 ): 706 - 716 . 24319254 10.1182/blood-2013-05-500033 PMC3907756
45. Du T Song Y Ray A Chauhan D Anderson KC . Proteomic analysis identifies mechanism (s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13 . Leukemia . 2020 May 18. doi: 10.1038/s41375-020-0865-2. [Epub ahead of print] 10.1038/s41375-020-0865-2 PMC7988682 32424294
46. Song Y Park PMC Wu L . Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma . Leukemia . 2019 ; 33 ( 11 ): 2685 - 2694 . 30962579 10.1038/s41375-019-0467-z PMC6783320
47. Shaffer AL Emre NC Lamy L . IRF4 addiction in multiple myeloma . Nature . 2008 ; 454 ( 7201 ): 226 - 231 . 18568025 10.1038/nature07064 PMC2542904
48. Ohguchi H Hideshima T Bhasin MK . The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival . Nat Commun . 2016 ; 7 : 10258 . 26728187 10.1038/ncomms10258 PMC4728406
49. Kronke J Udeshi ND Narla A . Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells . Science . 2014 ; 343 ( 6168 ): 301 - 305 . 24292625 10.1126/science.1244851 PMC4077049
50. Lu G Middleton RE Sun H . The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins . Science . 2014 ; 343 ( 6168 ): 305 - 309 . 24292623 10.1126/science.1244917 PMC4070318
51. Winter GE Buckley DL Paulk J . Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation . Science . 2015 ; 348 ( 6241 ): 1376 - 1381 . 25999370 10.1126/science.aab1433 PMC4937790
52. Walker BA Mavrommatis K Wardell CP . Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma . Blood . 2018 ; 132 ( 6 ): 587 - 597 . 29884741 10.1182/blood-2018-03-840132 PMC6097138
53. Chesi M Robbiani DF Sebag M . AIDdependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies . Cancer Cell . 2008 ; 13 ( 2 ): 167 - 180 . 18242516 10.1016/j.ccr.2008.01.007 PMC2255064
54. Jovanovic KK Roche-Lestienne C Ghobrial IM Facon T Quesnel B Manier S. Targeting MYC in multiple myeloma . Leukemia . 2018 ; 32 ( 6 ): 1295 - 1306 . 29467490 10.1038/s41375-018-0036-x
55. Fulciniti M Lin CY Samur MK . Nonoverlapping control of transcriptome by promoter- and super-enhancer-associated dependencies in multiple myeloma . Cell Rep . 2018 ; 25 ( 13 ): 3693 - 3705e6 . 30590042 10.1016/j.celrep.2018.12.016 PMC6407615
56. Bolli N Avet-Loiseau H Wedge DC . Heterogeneity of genomic evolution and mutational profiles in multiple myeloma . Nat Commun . 2014 ; 5 : 2997 . 24429703 10.1038/ncomms3997 PMC3905727
57. Perrot A Corre J Avet-Loiseau H. Risk stratification and targets in multiple myeloma: from genomics to the bedside . Am Soc Clin Oncol Educ Book . 2018 ; 38 : 675 - 680 . 30231368 10.1200/EDBK_200879
58. Corre J Cleynen A Robiou du Pont S . Multiple myeloma clonal evolution in homogeneously treated patients . Leukemia . 2018 ; 32 ( 12 ): 2636 - 2647 . 29895955 10.1038/s41375-018-0153-6 PMC6603429
59. Ledergor G Weiner A Zada M . Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma . Nat Med . 2018 ; 24 ( 12 ): 1867 - 1876 . 30523328 10.1038/s41591-018-0269-2
60. Study tests targeted drugs for multiple myeloma . Cancer Discov . 2019 ; 9 ( 4 ): 459 . doi:10.1158/2159-8290.CD-NB2019-014. 10.1158/2159-8290.CD-NB2019-014 30737227
61. Cottini F Hideshima T Suzuki R . Synthetic lethal approaches exploiting DNA damage in aggressive myeloma . Cancer Discov . 2015 ; 5 ( 9 ): 972 - 987 . 26080835 10.1158/2159-8290.CD-14-0943 PMC4560623
62. Shammas MA Shmookler Reis RJ Koley H Batchu RB Li C Munshi NC . Dysfunctional homologous recombination mediates genomic instability and progression in myeloma . Blood . 2009 ; 113 ( 10 ): 2290 - 2297 . 19050310 10.1182/blood-2007-05-089193 PMC2652372
63. Cottini F Hideshima T Xu C . Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers . Nat Med . 2014 ; 20 ( 6 ): 599 - 606 . 24813251 10.1038/nm.3562 PMC4057660
64. Amodio N D'Aquila P Passarino G Tassone P Bellizzi D. Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation . Expert Opin Ther Targets . 2017 ; 21 ( 1 ): 91 - 101 . 27892767 10.1080/14728222.2016.1266339
65. Ohguchi H Hideshima T Anderson KC . The biological significance of histone modifiers in multiple myeloma: clinical applications . Blood Cancer J . 2018 ; 8 ( 9 ): 83 . 30190472 10.1038/s41408-018-0119-y PMC6127133
66. Mirabella F Wu P Wardell CP . MMSET is the key molecular target in t(4;14) myeloma . Blood Cancer J . 2013 ; 3 : e114 . 23645128 10.1038/bcj.2013.9 PMC3674460
67. Gulla A Hideshima T Bianchi G . Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma . Leukemia . 2018 ; 32 ( 4 ): 996 - 1002 . 29158558 10.1038/leu.2017.334 PMC5871539
68. San-Miguel JF Hungria VT Yoon SS . Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial . Lancet Haematol . 2016 ; 3 ( 11 ): e506 - e515 . 27751707 10.1016/S2352-3026(16)30147-8
69. Hideshima T Qi J Paranal RM . Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma . Proc Natl Acad Sci U S A . 2016 ; 113 ( 46 ): 13162 - 13167 . 27799547 10.1073/pnas.1608067113 PMC5135369
70. Vogl DT Raje N Jagannath S . Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma . Clin Cancer Res . 2017 ; 23 ( 13 ): 3307 - 3315 . 28053023 10.1158/1078-0432.CCR-16-2526 PMC5496796
71. Bartel DP . MicroRNAs: genomics, biogenesis, mechanism, and function . Cell . 2004 ; 116 ( 2 ): 281 - 297 . 14744438 10.1016/s0092-8674(04)00045-5
72. Leone E Morelli E Di Martino MT . Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth . Clin Cancer Res . 2013 ; 19 ( 8 ): 2096 - 2106 . 23446999 10.1158/1078-0432.CCR-12-3325 PMC4147955
73. Morelli E Biamonte L Federico C . Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 . Blood . 2018 ; 132 ( 10 ): 1050 - 1063 . 29997223 10.1182/blood-2018-03-836601 PMC6128086
74. Amodio N Stamato MA Gulla AM . Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma . Mol Cancer Ther . 2016 ; 15 ( 6 ): 1364 - 1375 . 27196750 10.1158/1535-7163.MCT-15-0985
75. Di Martino MT Leone E Amodio N . Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence . Clin Cancer Res . 2012 ; 18 ( 22 ): 6260 - 6270 . 23035210 10.1158/1078-0432.CCR-12-1708 PMC4453928
76. Morelli E Leone E Cantafio ME . Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces antimultiple myeloma activity in vitro and in vivo . Leukemia . 2015 ; 29 ( 11 ): 2173 - 2183 . 25987254 10.1038/leu.2015.124 PMC4635336
77. Caracciolo D Di Martino MT Amodio N . miR-22 suppresses DNA ligase III addiction in multiple myeloma . Leukemia . 2019 ; 33 ( 2 ): 487 - 498 . 30120376 10.1038/s41375-018-0238-2 PMC6365379
78. Gulla A Di Martino MT Gallo Cantafio ME . A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells . Clin Cancer Res . 2016 ; 22 ( 5 ): 1222 - 1233 . 26527748 10.1158/1078-0432.CCR-15-0489 PMC4775414
79. Zhao JJ Chu ZB Hu Y . Targeting the miR-221-222/PUMA/BAK/BAX pathway abrogates dexamethasone resistance in multiple myeloma . Cancer Res . 2015 ; 75 ( 20 ): 4384 - 4397 . 26249174 10.1158/0008-5472.CAN-15-0457 PMC4609291
80. Botta C Cuce M Pitari MR . MiR-29b antagonizes the pro-inflammatory tumorpromoting activity of multiple myelomaeducated dendritic cells . Leukemia . 2018 ; 32 ( 4 ): 1003 - 1015 . 29158557 10.1038/leu.2017.336 PMC5886056
81. Pitari MR Rossi M Amodio N . Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts . Oncotarget . 2015 ; 6 ( 29 ): 27343 - 27358 . 26160841 10.18632/oncotarget.4398 PMC4694994
82. Hong DS Kang YK Borad M . Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours . Br J Cancer . 2020 ; 122 ( 11 ): 1630 - 1637 . 32238921 10.1038/s41416-020-0802-1 PMC7251107
83. Rupaimoole R Slack FJ . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases . Nat Rev Drug Discov . 2017 ; 16 ( 3 ): 203 - 222 . 28209991 10.1038/nrd.2016.246
84. Morelli E Gulla A Rocca R . The noncoding RNA landscape of plasma cell dyscrasias . Cancers (Basel) . 2020 ; 12 ( 2 ). 10.3390/cancers12020320 PMC7072200 32019064
85. Amodio N Stamato MA Juli G . Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity . Leukemia . 2018 ; 32 ( 9 ): 1948 - 1957 . 29487387 10.1038/s41375-018-0067-3 PMC6127082
86. Samur MK Minvielle S Gulla A . Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma . Leukemia . 2018 ; 32 ( 12 ): 2626 - 2635 . 29749396 10.1038/s41375-018-0116-y PMC6163089
87. Chesi M Mirza NN Garbitt VM . IAP antagonists induce anti-tumor immunity in multiple myeloma . Nat Med . 2016 ; 22 ( 12 ): 1411 - 1420 . 27841872 10.1038/nm.4229 PMC5515246
88. Fan F Bashari MH Morelli E . The AP- 1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment . Leukemia . 2017 ; 31 ( 7 ): 1570 - 1581 . 27890927 10.1038/leu.2016.358
89. Dimopoulos M Spencer A Attal M . Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma . N Engl J Med . 2007 ; 357 ( 21 ): 2123 - 2132 . 18032762 10.1056/NEJMoa070594
90. McCarthy PL Owzar K Hofmeister CC . Lenalidomide after stem-cell transplantation for multiple myeloma . N Engl J Med . 2012 ; 366 ( 19 ): 1770 - 1781 . 22571201 10.1056/NEJMoa1114083 PMC3744390
91. Benboubker L Dimopoulos MA Dispenzieri A . Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma . N Engl J Med . 2014 ; 371 ( 10 ): 906 - 917 . 25184863 10.1056/NEJMoa1402551
92. Miguel JS Weisel K Moreau P . Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial . Lancet Oncol . 2013 ; 14 ( 11 ): 1055 - 1066 . 24007748 10.1016/S1470-2045(13)70380-2
93. Davies F Baz R. Lenalidomide mode of action: linking bench and clinical findings . Blood Rev . 2010 ; 24 ( Suppl 1 ): S13 - S19 . 21126632 10.1016/S0268-960X(10)70004-7
94. Gandhi AK Kang J Havens CG . Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN) . Br J Haematol . 2014 ; 164 ( 6 ): 811 - 821 . 24328678 10.1111/bjh.12708 PMC4232904
95. Hideshima T Ogiya D Liu J . Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways . Leukemia . 2020 Apr 1. doi.org/10.1038/s41375-020-0809-x. [Epub ahead of print] 10.1038/s41375-020-0809-x PMC7529681 32238854
96. Luptakova K Rosenblatt J Glotzbecker B . Lenalidomide enhances anti-myeloma cellular immunity . Cancer Immunol Immunother . 2013 ; 62 ( 1 ): 39 - 49 . 22733396 10.1007/s00262-012-1308-3 PMC4098790
97. Facon T Kumar S Plesner T . Daratumumab plus lenalidomide and dexamethasone for untreated myeloma . N Engl J Med . 2019 ; 380 ( 22 ): 2104 - 2115 . 31141632 10.1056/NEJMoa1817249 PMC10045721
98. Dimopoulos MA Oriol A Nahi H . Daratumumab, lenalidomide, and dexamethasone for multiple myeloma . N Engl J Med . 2016 ; 375 ( 14 ): 1319 - 1331 . 27705267 10.1056/NEJMoa1607751
99. Dimopoulos MA Dytfeld D Grosicki S . Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma . N Engl J Med . 2018 ; 379 ( 19 ): 1811 - 1822 . 30403938 10.1056/NEJMoa1805762
100. Lonial S Dimopoulos M Palumbo A . Elotuzumab therapy for relapsed or refractory multiple myeloma . N Engl J Med . 2015 ; 373 ( 7 ): 621 - 631 . 26035255 10.1056/NEJMoa1505654
101. Attal M Richardson PG Rajkumar SV . Isatuximab plus pomalidomide and lowdose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study . Lancet . 2019 ; 394 ( 10214 ): 2096 - 2107 . 31735560 10.1016/S0140-6736(19)32556-5
102. Martin T Baz R Benson DM . A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma . Blood . 2017 ; 129 ( 25 ): 3294 - 3303 . 28483761 10.1182/blood-2016-09-740787 PMC5482100
103. Bjorklund CC Kang J Amatangelo M . Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN . Leukemia . 2020 ; 34 ( 4 ): 1197 - 1201 . 31719682 10.1038/s41375-019-0620-8 PMC7214241
104. Hansen JD Correa M Nagy MA . Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma . J Med Chem . 2020 ; 63 ( 13 ): 6648 - 6676 . 32130004 10.1021/acs.jmedchem.9b01928
105. Zavidij O Haradhvala NJ Mouhieddine TH . Ghobrial single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma . Nature Cancer . 2020 Apr 27. doi.org/10.1038/s43018-020-0053-3. [Epub ahead of print] 10.1038/s43018-020-0053-3 PMC7785110 33409501
106. Chauhan D Singh AV Brahmandam M . Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target . Cancer Cell . 2009 ; 16 ( 4 ): 309 - 323 . 19800576 10.1016/j.ccr.2009.08.019 PMC2762396
107. Ray A Das DS Song Y . A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells . Leukemia . 2017 ; 31 ( 12 ): 2652 - 2660 . 28479592 10.1038/leu.2017.135 PMC5737925
108. Ray A Tian Z Das DS . A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib . Leukemia . 2014 ; 28 ( 8 ): 1716 - 1724 . 24476765 10.1038/leu.2014.46 PMC4116471
109. Ray A Song Y Chauhan D Anderson KC . Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers antimyeloma immunity . Blood Cancer J . 2019 ; 9 ( 8 ): 64 . 31406111 10.1038/s41408-019-0224-6 PMC6690908
110. Holthof LC Mutis T. Challenges for immunotherapy in multiple myeloma: bone marrow microenvironment-mediated immune suppression and immune resistance . Cancers (Basel) . 2020 ; 12 ( 4 ). 10.3390/cancers12040988 PMC7226482 32316450
111. Costello C . The future of checkpoint inhibition in multiple myeloma? Lancet Haematol . 2019 ; 6 ( 9 ): e439 - e440 . 31327688 10.1016/S2352-3026(19)30149-8
112. Costa F Das R Kini Bailur J Dhodapkar K Dhodapkar MV . Checkpoint inhibition in myeloma: opportunities and challenges . Front Immunol . 2018 ; 9 : 2204 . 30319648 10.3389/fimmu.2018.02204 PMC6168958
113. Wudhikarn K Wills B Lesokhin AM . Monoclonal antibodies in multiple myeloma: current and emerging targets and mechanisms of action . Best Pract Res Clin Haematol . 2020 ; 33 ( 1 ): 101143 . 32139009 10.1016/j.beha.2020.101143 PMC7060936
114. Chari A Martinez-Lopez J Mateos MV . Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma . Blood . 2019 ; 134 ( 5 ): 421 - 431 . 31113777 10.1182/blood.2019000722 PMC6676132
115. Spencer A Lentzsch S Weisel K . Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR . Haematologica . 2018 ; 103 ( 12 ): 2079 - 2087 . 30237264 10.3324/haematol.2018.194118 PMC6269293
116. Voorhees PM Kaufman JL Laubach JP . Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: GRIFFIN . Blood . 2020 Apr 23. doi: 10.1182/blood.2020005288. [Epub ahead of print] 10.1182/blood.2020005288 PMC7441167 32325490
117. Mateos MV Nahi H Legiec W . Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial . Lancet Haematol . 2020 ; 7 ( 5 ): e370 - e380 . 32213342 10.1016/S2352-3026(20)30070-3
118. Cho SF Anderson KC Tai YT . Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMAbased immunotherapy . Front Immunol . 2018 ; 9 : 1821 . 30147690 10.3389/fimmu.2018.01821 PMC6095983
119. Xing L Lin L Yu T . A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma . Leukemia . 2020 Feb 14. doi: 10.1038/s41375-020-0745-9. [Epub ahead of print] 10.1038/s41375-020-0745-9 PMC7392808 32060401
120. Trudel S Lendvai N Popat R . Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial . Lancet Oncol . 2018 ; 19 ( 12 ): 1641 - 1653 . 30442502 10.1016/S1470-2045(18)30576-X PMC6328058
121. Kinneer K Meekin J Tiberghien AC . SLC46A3 as a potential predictive biomarker for antibody-drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads . Clin Cancer Res . 2018 ; 24 ( 24 ): 6570 - 6582 . 30131388 10.1158/1078-0432.CCR-18-1300
122. Tai YT Mayes PA Acharya C . Novel anti-B-cell maturation antigen antibodydrug conjugate (GSK2857916) selectively induces killing of multiple myeloma . Blood . 2014 ; 123 ( 20 ): 3128 - 3138 . 24569262 10.1182/blood-2013-10-535088 PMC4023420
123. Tai YT Acharya C An G . APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment . Blood . 2016 ; 127 ( 25 ): 3225 - 3236 . 27127303 10.1182/blood-2016-01-691162 PMC4920023
124. Frerichs KA Broekmans MEC Marin Soto JA . Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab . Clin Cancer Res . 2020 ; 26 ( 9 ): 2203 - 2215 . 31969333 10.1158/1078-0432.CCR-19-2299
125. Seckinger A Delgado JA Moser S . Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment . Cancer Cell . 2017 ; 31 ( 3 ): 396 - 410 . 28262554 10.1016/j.ccell.2017.02.002
126. Hipp S Tai YT Blanset D . A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo . Leukemia . 2017 ; 31 ( 8 ): 1743 - 1751 . 28025583 10.1038/leu.2016.388
127. Noonan KA Huff CA Davis J . Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma . Sci Transl Med . 2015 ; 7 ( 288 ): 288 ra78. 10.1126/scitranslmed.aaa7014 PMC4634889 25995224
128. Rodriguez-Otero P Paiva B Engelhardt M Prosper F San Miguel JF . Is immunotherapy here to stay in multiple myeloma? Haematologica . 2017 ; 102 ( 3 ): 423 - 432 . 28082344 10.3324/haematol.2016.152504 PMC5394971
129. D'Agostino M Raje N. Anti-BCMA CAR Tcell therapy in multiple myeloma: can we do better? Leukemia . 2020 ; 34 ( 1 ): 21 - 34 . 31780814 10.1038/s41375-019-0669-4
130. Yan Z Cao J Cheng H . A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial . Lancet Haematol . 2019 ; 6 ( 10 ): e521 - e529 . 31378662 10.1016/S2352-3026(19)30115-2
131. Raje N Berdeja J Lin Y . Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma . N Engl J Med . 2019 ; 380 ( 18 ): 1726 - 1737 . 31042825 10.1056/NEJMoa1817226 PMC8202968
132. Xu J Chen LJ Yang SS . Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma . Proc Natl Acad Sci U S A . 2019 ; 116 ( 19 ): 9543 - 9551 . 30988175 10.1073/pnas.1819745116 PMC6510991
133. Bae J Smith R Daley J . Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders . Clin Cancer Res . 2012 ; 18 ( 17 ): 4850 - 4860 . 22753586 10.1158/1078-0432.CCR-11-2776 PMC3839582
134. Bae J Prabhala R Voskertchian A . A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients . Leukemia . 2015 ; 29 ( 1 ): 218 - 229 . 24935722 10.1038/leu.2014.159 PMC4237716
135. Bae J Samur M Richardson P Munshi NC Anderson KC . Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8(+) cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy . Leukemia . 2019 ; 33 ( 9 ): 2208 - 2226 . 30872779 10.1038/s41375-019-0414-z PMC6728221
136. Rosenblatt J Avivi I Vasir B . Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients . Clin Cancer Res . 2013 ; 19 ( 13 ): 3640 - 3648 . 23685836 10.1158/1078-0432.CCR-13-0282 PMC3755905
137. Chari A Vogl DT Gavriatopoulou M . Oral selinexor-dexamethasone for tripleclass refractory multiple myeloma . N Engl J Med . 2019 ; 381 ( 8 ): 727 - 738 . 31433920 10.1056/NEJMoa1903455
138. Tassone P Neri P Carrasco DR . A clinically relevant SCID-hu in vivo model of human multiple myeloma . Blood . 2005 ; 106 ( 2 ): 713 - 716 . 15817674 10.1182/blood-2005-01-0373 PMC1895174
139. Calimeri T Battista E Conforti F . A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells . Leukemia . 2011 ; 25 ( 4 ): 707 - 711 . 21233838 10.1038/leu.2010.300 PMC3089835
140. Radl J Punt YA van den Enden-Vieveen MH . The 5T mouse multiple myeloma model: absence of c-myc oncogene rearrangement in early transplant generations . Br J Cancer . 1990 ; 61 ( 2 ): 276 - 278 . 2310679 10.1038/bjc.1990.51 PMC1971422
141. Calcinotto A Brevi A Chesi M . Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression . Nat Commun . 2018 ; 9 ( 1 ): 4832 . 30510245 10.1038/s41467-018-07305-8 PMC6277390
142. Peled JU Devlin SM Staffas A . Intestinal microbiota and relapse after hematopoietic-cell transplantation . J Clin Oncol . 2017 ; 35 ( 15 ): 1650 - 1659 . 28296584 10.1200/JCO.2016.70.3348 PMC5455763
143. Pianko MJ Devlin SM Littmann ER . Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition . Blood Adv . 2019 ; 3 ( 13 ): 2040 - 2044 . 31289031 10.1182/bloodadvances.2019032276 PMC6616258
144. Touzeau C Maciag P Amiot M Moreau P. Targeting Bcl-2 for the treatment of multiple myeloma . Leukemia . 2018 ; 32 ( 9 ): 1899 - 1907 . 30076373 10.1038/s41375-018-0223-9
145. Kumar S Kaufman JL Gasparetto C . Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma . Blood . 2017 ; 130 ( 22 ): 2401 - 2409 . 29018077 10.1182/blood-2017-06-788786
146. Moreau P Chanan-Khan A Roberts AW . Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM . Blood . 2017 ; 130 ( 22 ): 2392 - 2400 . 28847998 10.1182/blood-2017-06-788323
147. Lagana A Beno I Melnekoff D . Precision medicine for relapsed multiple myeloma on the basis of an integrative multiomics approach . JCO Precis Oncol . 2018 ; 2018 . 10.1200/PO.18.00019 PMC6350920 30706044
148. Moreau P Attal M Hulin C . Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study . Lancet . 2019 ; 394 ( 10192 ): 29 - 38 . 31171419 10.1016/S0140-6736(19)31240-1
149. Richardson PG Bringhen S Voorhees P . Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study . Lancet Haematol . 2020 ; 7 ( 5 ): e395 - e407 . 32213344 10.1016/S2352-3026(20)30044-2
150. Schjesvold F Robak P Pour L Aschan J Sonneveld P. OCEAN: a randomized phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma . Future Oncol . 2020 ; 16 ( 11 ): 631 - 641 . 32141766 10.2217/fon-2020-0024